Drug intelligence / Profile preview

triamcinolone + nepafenac

Development stage
Unknown
Lead developer
Harrow
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravitreal, Ophthalmic
01

Overview

Triamcinolone + nepafenac is a combination of two pharmaceutical agents used primarily in ophthalmology. Triamcinolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory properties, often administered via intravitreal injection to reduce inflammation and edema in the posterior segment of the eye. Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) formulated as an ophthalmic suspension; it acts as a prodrug that is converted by intraocular hydrolases to amfenac, which inhibits cyclooxygenase (COX) enzymes and reduces prostaglandin synthesis, thereby decreasing ocular pain and inflammation. This combination may be considered for conditions such as cystoid macular edema or post-surgical inflammation where both steroidal and nonsteroidal anti-inflammatory effects are desired[1][2][3]. However, clinical studies have not consistently shown added benefit from combining these agents compared to monotherapy[1].

02

Targets

GR (Glucocorticoid receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on triamcinolone + nepafenac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on triamcinolone + nepafenac.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call